Program
BI 3812465
A development code. Also written as “Low dose BI 3812465”, “Medium dose BI 3812465” and “High dose BI 3812465”.
Its studies are mostly in Macular Edema, led by Boehringer Ingelheim.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 11 open or running | phase 2since Apr 22, 2026 | Apr 22, 2026 | Mar 23, 2027phase 2 · NCT07553429 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 22, 2026First study: phase 2 study in Diabetic Macular EdemaFirst studyNCT07553429 · 49 planned · United States, Puerto Rico
Ahead
- Mar 23, 2027Primary completion: phase 2 study in Diabetic Macular EdemaNCT07553429
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07553429Diabetic Macular Edema · United States, Puerto Rico | 2 | Recruiting | Mar 23, 2027 | 49 |
How it is read
Names in the registry
- “Low dose BI 3812465”, 1 entry
- “Medium dose BI 3812465”, 1 entry
- “High dose BI 3812465”, 1 entry
Codes read as this program: BI3812465.
Conditions, from the studies’ own filings
- Macular Edema, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.